We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
HealthEquity posted strong fiscal Q2 results, with revenues up 7.6% and adjusted EPS rising 14.8%.
HSA assets reached $37.9 billion, while HSAs with investments increased 20% year over year.
AI reduced service costs, while HealthEquity raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million.
HealthEquity, Inc. (HQY - Free Report) has been gaining from its business model and strategy. The optimism, led by a solid second-quarter fiscal 2027 performance and strength in Health Savings Accounts (HSAs), is expected to contribute further. However, data security threats are major concerns.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have lost 0.6% against the 2.7% growth of the industry. The S&P 500 has increased 14.7% during the said time frame.
The renowned provider of technology-enabled services platforms for healthcare savings and spending decisions has a market capitalization of $7.57 billion. The company projects 16.1% growth over the next five years and expects to witness continued improvements in its business. HealthEquity’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.7%.
AI reduced service costs, while HealthEquity raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million.
Image Source: Zacks Investment Research
Reasons Favoring HQY’s Growth
Expansion of Health Savings Accounts: HealthEquity has experienced significant growth in its HSA offerings. HealthEquity reported 939,000 HSAs with investments as of July 31, 2026, up 20% year over year. Total accounts were 17.8 million, up 4% year over year. This included 10.7 million HSAs and 7.0 million Consumer Directed Benefits (CDBs).
Total HSA assets were $37.9 billion as of July 31, 2026. This included $17.4 billion of HSA cash, up 2%, and $20.6 billion of HSA investments, up 28%. The increase in HSA investments reflected higher market values and transfers from HSA cash, while HSA cash growth was supported by net contributions from new and existing members.
Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $931 million as of July 31, 2026, up 14% year over year.
AI & Digital Innovation Drive Scalable Efficiency:In second-quarter fiscal 2027, AI resolved 85% of routine chat inquiries and contained 55% of card-related phone contacts. Human-handled calls decreased 25% year over year, while card-related calls declined 30%. Management said that the next phase will focus more heavily on client service and back-office workflows, including onboarding, file transparency and claims automation. These efforts contributed to lower service costs per account and a 48% adjusted EBITDA margin in the quarter. Fiscal 2027 adjusted EBITDA guidance was raised to $628-$636 million, reinforcing continued investment alongside operating leverage.
Strong Fiscal Q2 Results: HealthEquity reported adjusted earnings of $1.24 per share for second-quarter fiscal 2027, beating the Zacks Consensus Estimate by 4.2% and rising 14.8% year over year. Revenues increased 7.6% to $350.7 million, driven by double-digit custodial revenue growth, a 14% rise in HSA assets to $37.9 billion and 24% growth in new HSA sales. Margin expansion remained a highlight, with gross margin improving 220 basis points to 73.5% and operating margin expanding to 28.1%.
HealthEquity also strengthened its financial position, with operating cash flow improving and debt declining sequentially. The company raised its fiscal 2027 revenue guidance to $1.411-$1.421 billion while reaffirming adjusted earnings guidance of $4.66-$4.73 per share, reflecting confidence in sustained HSA growth and disciplined execution.
Factor That May Offset HQY’s Gains
Data Security Threats: HealthEquity manages sensitive personal data and large custodial balances, which keeps cybersecurity risk elevated despite recent progress in fraud reduction. The company remains subject to a consolidated putative class action related to a fiscal 2025 cybersecurity incident involving a business partner’s user account and is also subject to regulatory inquiries connected to that incident.
In May 2026, the company filed a renewed motion to compel arbitration, and the potential loss associated with the lawsuit and any regulatory action was not reasonably estimable based on available information. Any adverse outcome could increase costs, create operational distraction and impact member and client confidence, which can weigh on the long-term margin and growth profile.
Estimate Trend
HealthEquity has been witnessing a stable estimate revision trend for fiscal 2027. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has remained stable at $4.72.
The Zacks Consensus Estimate for third-quarter fiscal 2027 revenues is pegged at $347.3 million, implying a 7.8% rise from the year-ago reported number. The consensus mark for fiscal third-quarter EPS is pinned at $1.16, implying a 14.9% improvement year over year.
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
Key Takeaways
HealthEquity, Inc. (HQY - Free Report) has been gaining from its business model and strategy. The optimism, led by a solid second-quarter fiscal 2027 performance and strength in Health Savings Accounts (HSAs), is expected to contribute further. However, data security threats are major concerns.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have lost 0.6% against the 2.7% growth of the industry. The S&P 500 has increased 14.7% during the said time frame.
The renowned provider of technology-enabled services platforms for healthcare savings and spending decisions has a market capitalization of $7.57 billion. The company projects 16.1% growth over the next five years and expects to witness continued improvements in its business. HealthEquity’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.7%.
AI reduced service costs, while HealthEquity raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million.
Image Source: Zacks Investment Research
Reasons Favoring HQY’s Growth
Expansion of Health Savings Accounts: HealthEquity has experienced significant growth in its HSA offerings. HealthEquity reported 939,000 HSAs with investments as of July 31, 2026, up 20% year over year. Total accounts were 17.8 million, up 4% year over year. This included 10.7 million HSAs and 7.0 million Consumer Directed Benefits (CDBs).
Total HSA assets were $37.9 billion as of July 31, 2026. This included $17.4 billion of HSA cash, up 2%, and $20.6 billion of HSA investments, up 28%. The increase in HSA investments reflected higher market values and transfers from HSA cash, while HSA cash growth was supported by net contributions from new and existing members.
Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $931 million as of July 31, 2026, up 14% year over year.
AI & Digital Innovation Drive Scalable Efficiency:In second-quarter fiscal 2027, AI resolved 85% of routine chat inquiries and contained 55% of card-related phone contacts. Human-handled calls decreased 25% year over year, while card-related calls declined 30%. Management said that the next phase will focus more heavily on client service and back-office workflows, including onboarding, file transparency and claims automation. These efforts contributed to lower service costs per account and a 48% adjusted EBITDA margin in the quarter. Fiscal 2027 adjusted EBITDA guidance was raised to $628-$636 million, reinforcing continued investment alongside operating leverage.
Strong Fiscal Q2 Results: HealthEquity reported adjusted earnings of $1.24 per share for second-quarter fiscal 2027, beating the Zacks Consensus Estimate by 4.2% and rising 14.8% year over year. Revenues increased 7.6% to $350.7 million, driven by double-digit custodial revenue growth, a 14% rise in HSA assets to $37.9 billion and 24% growth in new HSA sales. Margin expansion remained a highlight, with gross margin improving 220 basis points to 73.5% and operating margin expanding to 28.1%.
HealthEquity also strengthened its financial position, with operating cash flow improving and debt declining sequentially. The company raised its fiscal 2027 revenue guidance to $1.411-$1.421 billion while reaffirming adjusted earnings guidance of $4.66-$4.73 per share, reflecting confidence in sustained HSA growth and disciplined execution.
Factor That May Offset HQY’s Gains
Data Security Threats: HealthEquity manages sensitive personal data and large custodial balances, which keeps cybersecurity risk elevated despite recent progress in fraud reduction. The company remains subject to a consolidated putative class action related to a fiscal 2025 cybersecurity incident involving a business partner’s user account and is also subject to regulatory inquiries connected to that incident.
In May 2026, the company filed a renewed motion to compel arbitration, and the potential loss associated with the lawsuit and any regulatory action was not reasonably estimable based on available information. Any adverse outcome could increase costs, create operational distraction and impact member and client confidence, which can weigh on the long-term margin and growth profile.
Estimate Trend
HealthEquity has been witnessing a stable estimate revision trend for fiscal 2027. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has remained stable at $4.72.
The Zacks Consensus Estimate for third-quarter fiscal 2027 revenues is pegged at $347.3 million, implying a 7.8% rise from the year-ago reported number. The consensus mark for fiscal third-quarter EPS is pinned at $1.16, implying a 14.9% improvement year over year.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.